Table 4.

Properties of mEPSCs measured in CA1 hippocampal neurons (top) and dorsomedial striatal neurons (bottom) of adult male rats exposed to 24-h MD (or control treatment) at PND3

	noMD VEH	noMD MIF	MD VEH	MD MIF	Condition × treatment	Condition (noMD vs MD)	Treatment (VEH vs MIF)
Hippocampus
Amplitude (pA)	18.9 ± 0.8	18.1 ± 0.6	18 ± 0.6	18.1 ± 0.7	F(3,61) = 0.5; p = 0.459	F(3,61) = 0.4; p = 0.525	F(3,61) = 0.2; p = 0.634
τ-Rise (ms)	4.2 ± 0.2	3.8 ± 0.2	3.7 ± 0.3	3.9 ± 0.2	F(3,62) = 2.3; p = 0.132	F(3,62) = 0.5; p = 0.483	F(3,62) = 0.1; p = 0.699
τ-Decay (ms)	11.6 ± 0.6	11.4 ± 0.7	11.2 ± 0.7	11.3 ± 0.7	F(3,62) = 0.0; p = 0.807	F(3,62) = 02.; p = 0.688	F(3,62) = 0.0; p = 0.896
Dorsomedial striatum
Amplitude (pA)	16.1 ± 1.3	16.7 ± 0.7	12.3 ± 0.9	15.7 ± 0.9	F(1,48) = 2.0; p = 0.161	F(1,48) = 5.7; p = 0.020	F(1,48) = 3.9; p = 0.052
τ-Rise (ms)	1.0 ± 0.1	1.0 ± 0.1	0.9 ± 0.1	0.9 ± 0.1	F(1,48) = 0.0; p = 0.940	F(1,48) = 2.2; p = 0.139	F(1,48) = 0.3; p = 0.860
τ-Decay (ms)	6.2 ± 0.5	6.2 ± 0.5	4.7 ± 0.4	5.5 ± 0.5	F(1,48) = 0.6; p = 0.424	F(1,48) = 5.2; p = 0.027	F(1,48) = 0.5; p = 0.483

Half of the animals were treated twice daily with MIF through oral gavage on PND26–PND28.